In this 2023 review published in The Journals of Gerontology: Series A, Freeberg et al. assess the current landscape of NAD+ precursor supplementation in humans, focusing on nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The authors highlight that NAD+ levels decline with age and in various disease states, contributing to
